Review



cd34 microbead kit ultrapure, human  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Miltenyi Biotec cd34 microbead kit ultrapure, human
    Cd34 Microbead Kit Ultrapure, Human, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 290 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34+microbeads/CD34+MicroBead+Kit+UltraPure%2C+human/custom%40130-100-453%4042603588
    Average 96 stars, based on 290 article reviews
    cd34 microbead kit ultrapure, human - by Bioz Stars, 2026-10
    96/100 stars

    Images

    Related Articles

    Cell Culture:

    Article Title: NR2F2/AGAP2 axis: regulating lipid synthesis to drive AML progression via AMPKα/ACC pathway
    Article Snippet: .. Then, cells were cultured with 100 μL of FcR Blocking Reagent and 100 μL of CD34 MicroBeads (#130-046-702, Miltenyi, Bergisch Gladbach, Germany) in 2–8°C for 30 min. LS column was placed in the magnetic field, and cell suspension was applied onto the column, the unlabeled cells were discarded. ..

    Article Title: NR2F2/AGAP2 axis: regulating lipid synthesis to drive AML progression via AMPKα/ACC pathway.
    Article Snippet: .. Then, cells were cultured with 100 μL of FcR Blocking Reagent and 100 μL of CD34 MicroBeads (#130-046-702, Miltenyi, Bergisch Gladbach, Germany) in 2–8°C for 30 min. LS column was placed in the magnetic field, and cell suspension was applied onto the column, the unlabeled cells were discarded. ..

    Blocking Assay:

    Article Title: NR2F2/AGAP2 axis: regulating lipid synthesis to drive AML progression via AMPKα/ACC pathway
    Article Snippet: .. Then, cells were cultured with 100 μL of FcR Blocking Reagent and 100 μL of CD34 MicroBeads (#130-046-702, Miltenyi, Bergisch Gladbach, Germany) in 2–8°C for 30 min. LS column was placed in the magnetic field, and cell suspension was applied onto the column, the unlabeled cells were discarded. ..

    Article Title: 8-Me-PIQ Expands Cord Blood CD34 + Hematopoietic Stem and Progenitor Cells via Metabolic Suppression and Inhibition of Ribosome Biogenesis.
    Article Snippet: UCB, once discarded as medical waste, has emerged as a critical alternative source of HSCs for allogeneic transplantation.. Its advantages over bone marrow (BM) and mobilized peripheral blood (PB) are well-documented: UCB is readily available, collected through a non-invasive procedure posing no risk to mother or infant, and can be cryopreserved for extended periods with minimal loss of function [1–3].. Indeed, functional HSCs with robust long-term repopulating capacity have been successfully recovered from units Rongzhen Jiang jianrzh@sjtu.edu.cn

    Article Title: NR2F2/AGAP2 axis: regulating lipid synthesis to drive AML progression via AMPKα/ACC pathway.
    Article Snippet: .. Then, cells were cultured with 100 μL of FcR Blocking Reagent and 100 μL of CD34 MicroBeads (#130-046-702, Miltenyi, Bergisch Gladbach, Germany) in 2–8°C for 30 min. LS column was placed in the magnetic field, and cell suspension was applied onto the column, the unlabeled cells were discarded. ..

    Suspension:

    Article Title: NR2F2/AGAP2 axis: regulating lipid synthesis to drive AML progression via AMPKα/ACC pathway
    Article Snippet: .. Then, cells were cultured with 100 μL of FcR Blocking Reagent and 100 μL of CD34 MicroBeads (#130-046-702, Miltenyi, Bergisch Gladbach, Germany) in 2–8°C for 30 min. LS column was placed in the magnetic field, and cell suspension was applied onto the column, the unlabeled cells were discarded. ..

    Article Title: NR2F2/AGAP2 axis: regulating lipid synthesis to drive AML progression via AMPKα/ACC pathway.
    Article Snippet: .. Then, cells were cultured with 100 μL of FcR Blocking Reagent and 100 μL of CD34 MicroBeads (#130-046-702, Miltenyi, Bergisch Gladbach, Germany) in 2–8°C for 30 min. LS column was placed in the magnetic field, and cell suspension was applied onto the column, the unlabeled cells were discarded. ..

    Cell Isolation:

    Article Title: Circadian fluctuation of soluble CD26 dictates the impact of the timing of cord blood transplantation on acute graft-versus-host disease
    Article Snippet: The isolated CD3+ T cells were cultured in AIM-V medium (A3021002, Gibco) at a concentration of 2 × 105 cells/mL. .. For CD34+ cell isolation, immunomagnetic depletion was performed via CD34 microbeads (130-046-702, Miltenyi Biotech) following the recommended protocol. .. The isolated CD34+ cells were cultured in either StemSpan SFEM II medium (09655, STEMCELL Technologies) at 1 × 104 cells per milliliter or MethoCultTM H4435 enriched medium (04435, STEMCELL Technologies) at a density of 500 cells per well.

    Isolation:

    Article Title: Alternative polyadenylation links RNA processing to iron metabolism in human erythropoiesis
    Article Snippet: Human umbilical cord blood (UCB) samples were processed by Histopaque-1077 (Sigma, Cat # 10 771) density gradient centrifugation. .. Mononuclear cells (MNCs) were isolated, and CD34 + HSPCs were enriched using CD34 MicroBeads (Miltenyi Biotec, Cat # 130–046-702) f according to the manufacturer’s instructions. ..

    Purification:

    Article Title: Novel humanized loss-of-function NF1 mouse model of juvenile myelomonocytic leukemia
    Article Snippet: DNase I (Stem Cell Technologies) was added during thawing to improve recovery. .. Cells were filtered through a 70-μm strainer, and CD34 + HSPCs were purified using CD34 MicroBeads and magnetic-activated cell sorting columns (catalog no. 130-046-702; Miltenyi) following the manufacturer’s protocol. .. Purified CD34 + UCB HSPCs were expanded in HSPCs media with StemSpan serum-free medium SFEM II (catalog no. 09605, Stem Cell Technologies), 100 ng/mL of each of human cytokines: stem cell factor (catalog no. 300-07, PeproTech), thrombopoietin (catalog no. 300-18), interleukin-6 (catalog no. 200-06), and Flt3 (catalog no. 300-19), as previously published.

    FACS:

    Article Title: Novel humanized loss-of-function NF1 mouse model of juvenile myelomonocytic leukemia
    Article Snippet: DNase I (Stem Cell Technologies) was added during thawing to improve recovery. .. Cells were filtered through a 70-μm strainer, and CD34 + HSPCs were purified using CD34 MicroBeads and magnetic-activated cell sorting columns (catalog no. 130-046-702; Miltenyi) following the manufacturer’s protocol. .. Purified CD34 + UCB HSPCs were expanded in HSPCs media with StemSpan serum-free medium SFEM II (catalog no. 09605, Stem Cell Technologies), 100 ng/mL of each of human cytokines: stem cell factor (catalog no. 300-07, PeproTech), thrombopoietin (catalog no. 300-18), interleukin-6 (catalog no. 200-06), and Flt3 (catalog no. 300-19), as previously published.

    Expressing:

    Article Title: PU.1 inhibition sensitizes stem-monocytic AML to BCL2 blockade
    Article Snippet: Genetic characterization of the leukemia samples included results of a clinical deep-sequencing panel of genes commonly mutated in hematologic malignancies (GeneTrails, OHSU Knight Diagnostics Laboratory). .. OCI-AML8227 cells were immunomagnetically fractionated for CD34 surface expression using CD34 Microbeads (Miltenyi Biotec #130-046-702). ..



    Similar Products

    96
    Miltenyi Biotec cd34 microbead kit ultrapure, human
    Cd34 Microbead Kit Ultrapure, Human, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34+microbeads/CD34+MicroBead+Kit+UltraPure%2C+human/custom%40130-100-453%4042603588
    Average 96 stars, based on 1 article reviews
    cd34 microbead kit ultrapure, human - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec magnetic selection
    Magnetic Selection, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34+microbeads/CD34+MicroBead+Kit+UltraPure%2C+human/pm42486681-84-6-8
    Average 96 stars, based on 1 article reviews
    magnetic selection - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec cd34 microbead kit ultrapure
    B cell development in ABOs is not driven by expansion of pre-existing B-lineage-committed <t>progenitor</t> <t>cells</t> (A) Flow cytometric analysis of <t>CD34,</t> c-KIT (CD117), CD38, and CD10 expression on HSPCs before (top) and after depletion of Lin + CD10 + cells (bottom) by MACS, visualized with opt-SNE. (B and C) Flow cytometric analysis comparing the frequencies of CD33 + myeloid-committed (B) and CD10 + CD38 + lymphoid-committed cells (C) in day 35 ABOs using bulk or Lin + CD10 + -depleted <t>CD34</t> + HSPCs. (D) Quantification of CD33 + and CD10 + CD38 + cells in day 35 ABOs. (E) Flow cytometric analysis comparing IgM + IgD − (immature) and IgM + IgD + (transitional) B cell frequencies in day 35 ABOs using bulk or Lin + CD10 + -depleted CD34 + HSPCs. (F) Quantification of IgM + and IgM + IgD + B cell frequencies in day 35 ABOs. (G) Distribution of HSPCs along the B cell developmental trajectory in day 35 ABOs. (D, F, G) Data are presented as mean ± SEM. Statistical analysis was performed using two-way ANOVA followed by Bonferroni’s multiple comparisons test (ns; non-significant). (A–G) Data represent n = 3 individual donors in independent cultures. See also .
    Cd34 Microbead Kit Ultrapure, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34+microbeads/CD34+MicroBead+Kit+UltraPure%2C+human/pmc13400188-422-23-27
    Average 96 stars, based on 1 article reviews
    cd34 microbead kit ultrapure - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    97
    Miltenyi Biotec macs human cd34 microbead kit
    B cell development in ABOs is not driven by expansion of pre-existing B-lineage-committed <t>progenitor</t> <t>cells</t> (A) Flow cytometric analysis of <t>CD34,</t> c-KIT (CD117), CD38, and CD10 expression on HSPCs before (top) and after depletion of Lin + CD10 + cells (bottom) by MACS, visualized with opt-SNE. (B and C) Flow cytometric analysis comparing the frequencies of CD33 + myeloid-committed (B) and CD10 + CD38 + lymphoid-committed cells (C) in day 35 ABOs using bulk or Lin + CD10 + -depleted <t>CD34</t> + HSPCs. (D) Quantification of CD33 + and CD10 + CD38 + cells in day 35 ABOs. (E) Flow cytometric analysis comparing IgM + IgD − (immature) and IgM + IgD + (transitional) B cell frequencies in day 35 ABOs using bulk or Lin + CD10 + -depleted CD34 + HSPCs. (F) Quantification of IgM + and IgM + IgD + B cell frequencies in day 35 ABOs. (G) Distribution of HSPCs along the B cell developmental trajectory in day 35 ABOs. (D, F, G) Data are presented as mean ± SEM. Statistical analysis was performed using two-way ANOVA followed by Bonferroni’s multiple comparisons test (ns; non-significant). (A–G) Data represent n = 3 individual donors in independent cultures. See also .
    Macs Human Cd34 Microbead Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34+microbeads/CD34+MicroBead+Kit%2C+human+-+lyophilized/pm42478052-103-2-7
    Average 97 stars, based on 1 article reviews
    macs human cd34 microbead kit - by Bioz Stars, 2026-10
    97/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec human cd34 microbead kit ultrapure
    NOX1i in Myeloid-HIS-HCC mice reduces monocyte and tumor-associated macrophage infiltration. (A) Schematic overview of the experimental set-up. Male NSG-SGM3 mice (n = 11) were sublethally irradiated and the immune system was partly reconstituted using human cord blood (CB)-derived hematopoietic stem and <t>progenitor</t> <t>cells</t> (HSPCs). Four weeks post humanization, orthotopic human HCC was induced and mice were treated with 50 µM ML171 (NOX1i; n = 6) or vehicle (n = 5), twice per week for 3 weeks. (B) Human-to-murine immune cell (CD45) chimerism in the indicated tissues. (C) Human engraftment based on the number of human CD45 cells. Data are represented as violin plots showing median and quartiles. (D,E) Human immune cell subsets (D) and monocyte subsets (E) in indicated tissues represented as percentage of human CD45 cells. (F) Number of human macrophages and monocytes in the indicated tissues. (G) Representative immunohistochemistry images of infiltrated human monocytes/macrophages in liver tissue of HCC-bearing humanized mice. Sections were stained for human CD14 (brown), or matched IgG control. Scale bars: 100 µm. (B,D,E) . Data are shown as mean (SD). (C–E) Adjusted p-values were calculated using multiple unpaired t-test with Holm-Šídák correction (D,E) , or p-values were calculated using unpaired t-test with Welch’s correction or unpaired Mann-Whitney U test based on normal distribution (C,E) . *p < 0.05. HCC: hepatocellular carcinoma, NOX1i: NOX1 inhibition, huCD45: human CD45, muCD45: murine CD45, NK = natural killer, DCs: dendritic cells.
    Human Cd34 Microbead Kit Ultrapure, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34+microbeads/CD34+MicroBead+Kit+UltraPure%2C+human/pmc13407187-53-28-33
    Average 96 stars, based on 1 article reviews
    human cd34 microbead kit ultrapure - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    97
    Miltenyi Biotec cd34 microbead kit
    ZEB1 is required for optimal TED in primary human cells. ( A ) Experimental scheme of ZEB1 KD in primary human <t>CD34</t> + HSPCs. ( B ) ZEB1 mRNA levels measured at day 3 of differentiation. ( C ) GPA levels at day 3 of erythroid differentiation. Percentages of GPA + cells are indicated. ( D ) Cell growth rates at days 3, 7, and 10. ( E ) Proportion of erythroid progenitors, pro-erythroblasts (Pro-E), and basophilic erythroblasts (Baso) at day 3 of erythroid differentiation. ( F ) mRNA levels of GATA2 and KLF1 in ZEB1 KD cells (day 3). ( G ) Enucleation rates measured by Syto-60 staining at day 10 of differentiation. Data are mean ± SEM of n = 3–5 independent biological experiments, from three independent blood donors, * P < .05, ** P < .01, *** P < .001, **** P < .0001 (Student’s t -test).
    Cd34 Microbead Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34+microbeads/CD34+MicroBead+Kit%2C+human/pmc13286653-125-9-13
    Average 97 stars, based on 1 article reviews
    cd34 microbead kit - by Bioz Stars, 2026-10
    97/100 stars
      Buy from Supplier

    97
    Miltenyi Biotec anti human fcr blocking reagent
    ZEB1 is required for optimal TED in primary human cells. ( A ) Experimental scheme of ZEB1 KD in primary human <t>CD34</t> + HSPCs. ( B ) ZEB1 mRNA levels measured at day 3 of differentiation. ( C ) GPA levels at day 3 of erythroid differentiation. Percentages of GPA + cells are indicated. ( D ) Cell growth rates at days 3, 7, and 10. ( E ) Proportion of erythroid progenitors, pro-erythroblasts (Pro-E), and basophilic erythroblasts (Baso) at day 3 of erythroid differentiation. ( F ) mRNA levels of GATA2 and KLF1 in ZEB1 KD cells (day 3). ( G ) Enucleation rates measured by Syto-60 staining at day 10 of differentiation. Data are mean ± SEM of n = 3–5 independent biological experiments, from three independent blood donors, * P < .05, ** P < .01, *** P < .001, **** P < .0001 (Student’s t -test).
    Anti Human Fcr Blocking Reagent, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34+microbeads/CD34+MicroBead+Kit%2C+human/pm42424945-88-0-4
    Average 97 stars, based on 1 article reviews
    anti human fcr blocking reagent - by Bioz Stars, 2026-10
    97/100 stars
      Buy from Supplier

    Image Search Results


    B cell development in ABOs is not driven by expansion of pre-existing B-lineage-committed progenitor cells (A) Flow cytometric analysis of CD34, c-KIT (CD117), CD38, and CD10 expression on HSPCs before (top) and after depletion of Lin + CD10 + cells (bottom) by MACS, visualized with opt-SNE. (B and C) Flow cytometric analysis comparing the frequencies of CD33 + myeloid-committed (B) and CD10 + CD38 + lymphoid-committed cells (C) in day 35 ABOs using bulk or Lin + CD10 + -depleted CD34 + HSPCs. (D) Quantification of CD33 + and CD10 + CD38 + cells in day 35 ABOs. (E) Flow cytometric analysis comparing IgM + IgD − (immature) and IgM + IgD + (transitional) B cell frequencies in day 35 ABOs using bulk or Lin + CD10 + -depleted CD34 + HSPCs. (F) Quantification of IgM + and IgM + IgD + B cell frequencies in day 35 ABOs. (G) Distribution of HSPCs along the B cell developmental trajectory in day 35 ABOs. (D, F, G) Data are presented as mean ± SEM. Statistical analysis was performed using two-way ANOVA followed by Bonferroni’s multiple comparisons test (ns; non-significant). (A–G) Data represent n = 3 individual donors in independent cultures. See also .

    Journal: Cell Reports Medicine

    Article Title: ABO: A 3D stroma-supported culture platform enabling full human B-lymphopoiesis for disease modeling and gene therapy development

    doi: 10.1016/j.xcrm.2026.102879

    Figure Lengend Snippet: B cell development in ABOs is not driven by expansion of pre-existing B-lineage-committed progenitor cells (A) Flow cytometric analysis of CD34, c-KIT (CD117), CD38, and CD10 expression on HSPCs before (top) and after depletion of Lin + CD10 + cells (bottom) by MACS, visualized with opt-SNE. (B and C) Flow cytometric analysis comparing the frequencies of CD33 + myeloid-committed (B) and CD10 + CD38 + lymphoid-committed cells (C) in day 35 ABOs using bulk or Lin + CD10 + -depleted CD34 + HSPCs. (D) Quantification of CD33 + and CD10 + CD38 + cells in day 35 ABOs. (E) Flow cytometric analysis comparing IgM + IgD − (immature) and IgM + IgD + (transitional) B cell frequencies in day 35 ABOs using bulk or Lin + CD10 + -depleted CD34 + HSPCs. (F) Quantification of IgM + and IgM + IgD + B cell frequencies in day 35 ABOs. (G) Distribution of HSPCs along the B cell developmental trajectory in day 35 ABOs. (D, F, G) Data are presented as mean ± SEM. Statistical analysis was performed using two-way ANOVA followed by Bonferroni’s multiple comparisons test (ns; non-significant). (A–G) Data represent n = 3 individual donors in independent cultures. See also .

    Article Snippet: Leukocytes from UCB and mPB were first purified using the Erythrocyte Sedimentation Kit II (Miltenyi), followed by CD34 + cell enrichment with the CD34 MicroBead Kit UltraPure (Miltenyi) per manufacturer’s instructions.

    Techniques: Expressing

    NOX1i in Myeloid-HIS-HCC mice reduces monocyte and tumor-associated macrophage infiltration. (A) Schematic overview of the experimental set-up. Male NSG-SGM3 mice (n = 11) were sublethally irradiated and the immune system was partly reconstituted using human cord blood (CB)-derived hematopoietic stem and progenitor cells (HSPCs). Four weeks post humanization, orthotopic human HCC was induced and mice were treated with 50 µM ML171 (NOX1i; n = 6) or vehicle (n = 5), twice per week for 3 weeks. (B) Human-to-murine immune cell (CD45) chimerism in the indicated tissues. (C) Human engraftment based on the number of human CD45 cells. Data are represented as violin plots showing median and quartiles. (D,E) Human immune cell subsets (D) and monocyte subsets (E) in indicated tissues represented as percentage of human CD45 cells. (F) Number of human macrophages and monocytes in the indicated tissues. (G) Representative immunohistochemistry images of infiltrated human monocytes/macrophages in liver tissue of HCC-bearing humanized mice. Sections were stained for human CD14 (brown), or matched IgG control. Scale bars: 100 µm. (B,D,E) . Data are shown as mean (SD). (C–E) Adjusted p-values were calculated using multiple unpaired t-test with Holm-Šídák correction (D,E) , or p-values were calculated using unpaired t-test with Welch’s correction or unpaired Mann-Whitney U test based on normal distribution (C,E) . *p < 0.05. HCC: hepatocellular carcinoma, NOX1i: NOX1 inhibition, huCD45: human CD45, muCD45: murine CD45, NK = natural killer, DCs: dendritic cells.

    Journal: Frontiers in Pharmacology

    Article Title: Harnessing human immune system models to validate NADPH oxidase 1 inhibition as treatment for hepatocellular carcinoma

    doi: 10.3389/fphar.2026.1808515

    Figure Lengend Snippet: NOX1i in Myeloid-HIS-HCC mice reduces monocyte and tumor-associated macrophage infiltration. (A) Schematic overview of the experimental set-up. Male NSG-SGM3 mice (n = 11) were sublethally irradiated and the immune system was partly reconstituted using human cord blood (CB)-derived hematopoietic stem and progenitor cells (HSPCs). Four weeks post humanization, orthotopic human HCC was induced and mice were treated with 50 µM ML171 (NOX1i; n = 6) or vehicle (n = 5), twice per week for 3 weeks. (B) Human-to-murine immune cell (CD45) chimerism in the indicated tissues. (C) Human engraftment based on the number of human CD45 cells. Data are represented as violin plots showing median and quartiles. (D,E) Human immune cell subsets (D) and monocyte subsets (E) in indicated tissues represented as percentage of human CD45 cells. (F) Number of human macrophages and monocytes in the indicated tissues. (G) Representative immunohistochemistry images of infiltrated human monocytes/macrophages in liver tissue of HCC-bearing humanized mice. Sections were stained for human CD14 (brown), or matched IgG control. Scale bars: 100 µm. (B,D,E) . Data are shown as mean (SD). (C–E) Adjusted p-values were calculated using multiple unpaired t-test with Holm-Šídák correction (D,E) , or p-values were calculated using unpaired t-test with Welch’s correction or unpaired Mann-Whitney U test based on normal distribution (C,E) . *p < 0.05. HCC: hepatocellular carcinoma, NOX1i: NOX1 inhibition, huCD45: human CD45, muCD45: murine CD45, NK = natural killer, DCs: dendritic cells.

    Article Snippet: Freshly isolated CB-derived PBMCs, isolated from CB as described for buffy coat, were enriched for HSPCs based on positive immunomagnetic selection of CD34 + expressing cells using the human CD34 MicroBead Kit UltraPure (Miltenyi Biotec, #130–100-453) according to manufacturer’s guidelines.

    Techniques: Irradiation, Derivative Assay, Immunohistochemistry, Staining, Control, MANN-WHITNEY, Inhibition

    ZEB1 is required for optimal TED in primary human cells. ( A ) Experimental scheme of ZEB1 KD in primary human CD34 + HSPCs. ( B ) ZEB1 mRNA levels measured at day 3 of differentiation. ( C ) GPA levels at day 3 of erythroid differentiation. Percentages of GPA + cells are indicated. ( D ) Cell growth rates at days 3, 7, and 10. ( E ) Proportion of erythroid progenitors, pro-erythroblasts (Pro-E), and basophilic erythroblasts (Baso) at day 3 of erythroid differentiation. ( F ) mRNA levels of GATA2 and KLF1 in ZEB1 KD cells (day 3). ( G ) Enucleation rates measured by Syto-60 staining at day 10 of differentiation. Data are mean ± SEM of n = 3–5 independent biological experiments, from three independent blood donors, * P < .05, ** P < .01, *** P < .001, **** P < .0001 (Student’s t -test).

    Journal: Nucleic Acids Research

    Article Title: ZEB1 drives terminal erythroid maturation by controlling the GATA2–KLF1 regulatory switch

    doi: 10.1093/nar/gkag613

    Figure Lengend Snippet: ZEB1 is required for optimal TED in primary human cells. ( A ) Experimental scheme of ZEB1 KD in primary human CD34 + HSPCs. ( B ) ZEB1 mRNA levels measured at day 3 of differentiation. ( C ) GPA levels at day 3 of erythroid differentiation. Percentages of GPA + cells are indicated. ( D ) Cell growth rates at days 3, 7, and 10. ( E ) Proportion of erythroid progenitors, pro-erythroblasts (Pro-E), and basophilic erythroblasts (Baso) at day 3 of erythroid differentiation. ( F ) mRNA levels of GATA2 and KLF1 in ZEB1 KD cells (day 3). ( G ) Enucleation rates measured by Syto-60 staining at day 10 of differentiation. Data are mean ± SEM of n = 3–5 independent biological experiments, from three independent blood donors, * P < .05, ** P < .01, *** P < .001, **** P < .0001 (Student’s t -test).

    Article Snippet: CD34 + were isolated by positive selection using the CD34 MicroBead Kit (MACS Miltenyi) according to the manufacturers’ recommendation and cultured following a human ex vivo differentiation protocol as previously described [ ].

    Techniques: Staining